» Articles » PMID: 21423719

Genome-wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits

Abstract

Nonalcoholic fatty liver disease (NAFLD) clusters in families, but the only known common genetic variants influencing risk are near PNPLA3. We sought to identify additional genetic variants influencing NAFLD using genome-wide association (GWA) analysis of computed tomography (CT) measured hepatic steatosis, a non-invasive measure of NAFLD, in large population based samples. Using variance components methods, we show that CT hepatic steatosis is heritable (∼26%-27%) in family-based Amish, Family Heart, and Framingham Heart Studies (n = 880 to 3,070). By carrying out a fixed-effects meta-analysis of genome-wide association (GWA) results between CT hepatic steatosis and ∼2.4 million imputed or genotyped SNPs in 7,176 individuals from the Old Order Amish, Age, Gene/Environment Susceptibility-Reykjavik study (AGES), Family Heart, and Framingham Heart Studies, we identify variants associated at genome-wide significant levels (p<5×10(-8)) in or near PNPLA3, NCAN, and PPP1R3B. We genotype these and 42 other top CT hepatic steatosis-associated SNPs in 592 subjects with biopsy-proven NAFLD from the NASH Clinical Research Network (NASH CRN). In comparisons with 1,405 healthy controls from the Myocardial Genetics Consortium (MIGen), we observe significant associations with histologic NAFLD at variants in or near NCAN, GCKR, LYPLAL1, and PNPLA3, but not PPP1R3B. Variants at these five loci exhibit distinct patterns of association with serum lipids, as well as glycemic and anthropometric traits. We identify common genetic variants influencing CT-assessed steatosis and risk of NAFLD. Hepatic steatosis associated variants are not uniformly associated with NASH/fibrosis or result in abnormalities in serum lipids or glycemic and anthropometric traits, suggesting genetic heterogeneity in the pathways influencing these traits.

Citing Articles

Impact of Sexual Dimorphism on Therapy Response in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: From Conventional and Nutritional Approaches to Emerging Therapies.

Dileo E, Saba F, Parasiliti-Caprino M, Rosso C, Bugianesi E Nutrients. 2025; 17(3).

PMID: 39940335 PMC: 11821005. DOI: 10.3390/nu17030477.


Impact of NAFLD-related SNPs on the carotid atherosclerosis development; a five-year prospective observational study.

Ikezaki H, Nakashima R, Matsumoto Y, Ohta A, Yamasaki S, Hiramine S Atheroscler Plus. 2025; 59():10-17.

PMID: 39802653 PMC: 11719292. DOI: 10.1016/j.athplu.2024.12.003.


A Very Low-Carbohydrate Program in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease and Phospholipase Domain-Containing Protein 3 Risk Genotype: Pre-Post Intervention Study.

Saslow L, Krinock J, OBrien A, Raymond K, Bayandorian H, Moskowitz J JMIR Form Res. 2025; 9():e60051.

PMID: 39801107 PMC: 11740387. DOI: 10.2196/60051.


Recent advances in MASLD genetics: Insights into disease mechanisms and the next frontiers in clinical application.

Chen V, Brady G Hepatol Commun. 2025; 9(1.

PMID: 39774697 PMC: 11717516. DOI: 10.1097/HC9.0000000000000618.


An epidemiological study on the factors including genetic polymorphism influencing ALT >30 U/L and liver fibrosis progression in metabolic dysfunction-associated steatotic liver disease among the general population.

Sato S, Iino C, Sasada T, Soma G, Furusawa K, Yoshida K JGH Open. 2024; 8(12):e70043.

PMID: 39713746 PMC: 11659511. DOI: 10.1002/jgh3.70043.


References
1.
Rampersaud E, Bielak L, Parsa A, Shen H, Post W, Ryan K . The association of coronary artery calcification and carotid artery intima-media thickness with distinct, traditional coronary artery disease risk factors in asymptomatic adults. Am J Epidemiol. 2008; 168(9):1016-23. PMC: 2720772. DOI: 10.1093/aje/kwn211. View

2.
Speliotes E, Willer C, Berndt S, Monda K, Thorleifsson G, Jackson A . Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010; 42(11):937-48. PMC: 3014648. DOI: 10.1038/ng.686. View

3.
Kathiresan S, Willer C, Peloso G, Demissie S, Musunuru K, Schadt E . Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2008; 41(1):56-65. PMC: 2881676. DOI: 10.1038/ng.291. View

4.
Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson A . New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010; 42(2):105-16. PMC: 3018764. DOI: 10.1038/ng.520. View

5.
Lindgren C, Heid I, Randall J, Lamina C, Steinthorsdottir V, Qi L . Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet. 2009; 5(6):e1000508. PMC: 2695778. DOI: 10.1371/journal.pgen.1000508. View